🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Manning & Napier Group’s CRL Holdings & Trades

First Buy
Q4 2022
Duration Held
15 Quarters
Largest Add
Q4 2022
+13,959 Shares
Current Position
14 Shares
$3,158 Value

Manning & Napier Group's CRL Position Overview

Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 14 shares of Charles River Laboratories International, Inc. (CRL) worth $3,158, representing 0.00% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 15 quarters.

Based on 13F filings, Manning & Napier Group has maintained a strategic position in CRL, demonstrating sustained confidence in this investment. Largest reduction occurred in Q2 2026, reducing 13,945 shares.

Analysis based on 13F filings available since 2013 Q2

Manning & Napier Group's Charles River Laboratories International (CRL) Holding Value Over Time

Track share changes against reported price movement

Quarterly Charles River Laboratories International (CRL) Trades by Manning & Napier Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +14 New Buy 14 $225.57
Q1 2023 -13,959 Sold Out 13,959 $217.90
Q4 2022 +13,959 New Buy 13,959 $217.90

Manning & Napier Group's Charles River Laboratories International Investment FAQs

Manning & Napier Group first purchased Charles River Laboratories International, Inc. (CRL) in Q4 2022, acquiring 13,959 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Manning & Napier Group has held Charles River Laboratories International, Inc. (CRL) for 15 quarters since Q4 2022.

Manning & Napier Group's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q4 2022, adding 13,959 shares worth $3.04 M.

According to the latest 13F filing for Q2 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 14 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $3,158.

As of the Q2 2026 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.

Manning & Napier Group's peak holding in Charles River Laboratories International, Inc. (CRL) was 13,959 shares, as reported at the end of Q4 2022.